Some researchers have found that IL4I1, as a prognostic biomarker, augments tumor growth by reprogramming TME in melanoma, kidney renal clear cell carcinoma (KIRC), and liver hepatocellular carcinoma (LIHC), which is attributed to its association with the movement and recruitment of leukocytes (20–23). Here, IL4I1 is linked to melanoma.